Evolent Health (EVH) Q2 2024 earnings summary

Executive summary

• Revenue for Q2 2024 grew 37.9% year-over-year to $647.1 million, driven by new contracts, rate increases, and expansion in specialty care offerings.

• Adjusted EBITDA reached $52.0 million with an 8.0% margin, and the company remains confident in achieving a $300 million adjusted EBITDA exit run rate for 2024.

• Net loss attributable to common shareholders narrowed to $6.4 million from $41.4 million a year ago, reflecting improved operating leverage and lower SG&A expenses.

• Four new revenue agreements were signed in Q2, expected to add over $70 million in annualized revenue, including expansions in oncology and musculoskeletal solutions.

• The 2023 Repositioning Plan concluded in Q2 2024, streamlining operations and reducing costs.

Financial highlights

• Q2 2024 revenue: $647.1 million, up from $469.1 million in Q2 2023; adjusted EBITDA: $52.0 million; net loss: $6.4 million; adjusted EBITDA margin: 8.0%.

• Adjusted gross margin for Q2: 16.7%, up sequentially; adjusted SG&A: $56.1 million, down year-over-year.

• Cash and cash equivalents at quarter-end: $101.3 million, after $88.8 million NIA earn-out payment.

• Net debt to adjusted EBITDA: 2.5x at quarter-end, improved from 3.3x a year ago.

• Adjusted income attributable to common shareholders was $34.6 million, with adjusted EPS of $0.30.

Outlook and guidance

• Q3 2024 revenue projected at $615–$635 million; adjusted EBITDA at $60–$68 million.

• Full-year 2024 revenue guidance raised to $2.56–$2.6 billion; adjusted EBITDA guidance: $230–$245 million.

• Cash flow from operations expected to exceed $150 million for the year; $25 million planned for capitalized software development.

• Temporary increase in OpEx due to Machinify integration, with $5 million shift from CapEx to OpEx in Q4.

• Rate increases and new business go-lives are expected to drive margin and EBITDA growth in the second half.